Left atrial appendage thrombus on full-dose dabigatran treatment: a case report.

ABSTRACT:

Background

Dabigatran is a direct competitive thrombin inhibitor approved for stroke prevention in non-valvular atrial fibrillation. At full-dose, dabigatran showed similar rates of bleedings and higher efficacy compared to warfarin.

Case summary

We report a case of acute ischaemic stroke in a patient treated with dabigatran 150 mg b.i.d. for atrial fibrillation. After an off-label treatment with idarucizumab, a humanized monoclonal antibody approved for dabigatran reversal, we performed a successful intravenous thrombolysis (IVT). Transoesophageal echocardiography showed a left atrial appendage (LAA) thrombus, despite full-dose dabigatran and an adequate therapy adherence.

Discussion

There are few cases of LAA thrombus during dabigatran treatment reported in literatu

SUBMITTER: Candelaresi P 

PROVIDER: S-EPMC7319812 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature